Market Overview:
The global clotting factor market is expected to grow at a CAGR of 5.5% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing incidence of bleeding disorders, rising awareness about available treatment options, and growing demand for recombinant clotting factors. Based on type, the global clotting factor market is segmented into clotting factor I, clotting factor II, clotting factor III, and others. Clotting factors I and III are the most commonly used types of recombinant proteins for treating hemophilia A and B respectively. These products are also known as coagulation factors or procoagulants. They play a key role in blood coagulation by converting fibrinogen into fibrin monomers that form clots to stop bleeding. Factor II (prothrombin) is also used extensively for treating patients with hemophilia A; however it has been largely replaced by recombinant Factor VIII (antihemophilic globulin). Based on application, the global market is segmented into hospitals, clinics, ambulatory surgical centers (ASCs), and others segments such as research laboratories and home care settings. Hospitals account for a major share of the overall demand for recombinant proteins due to high prevalence of bleeding disorders among patients admitted in these institutions .
Product Definition:
Clotting Factor is a plasma protein that helps blood clot. It is important for stopping bleeding.
Clotting Factor I:
Clotting factor i is a protein that helps stop blood from clotting when it is injured. It's main function in the human body is to help stop bleeding by promoting coagulation (the process of clumping). The normal level of clotting factor i in the human body is supposed to be between 1-7%. When there's an absence or deficiency of this protein, then it’s called as Factor I Deficiency.
Clotting Factor II:
Clotting factor II is a protein that helps blood to clot normally. It is also known as the coagulation factor II or anticoagulant protein. The normal level of this protein in humans is 1% to 5%. When the level of this protein falls below 0.8%, it becomes difficult for the body to coagulate (clot) blood and causes bleeding disorder called hemophilia A.
Application Insights:
The market is segmented by application into hospitals, clinics and ambulatory surgical centers. The clinics and ambulatory surgical centers held the largest share of the global clotting factor market in 2017. Factors are used in surgeries to reduce the risk of blood clots forming in the heart or lungs. These factors help dissolve existing blood clot so that it can be passed through urine or feces without causing any harm to organs such as kidneys or liver.
Regional Analysis:
North America dominated the global market in 2017. The presence of key players, advanced healthcare infrastructure and high adoption rate for technologically advanced products are some of the factors responsible for its large share. Moreover, increasing demand for blood clotting factor products due to rising prevalence of lifestyle-associated diseases such as cardiovascular disorders and cancer is expected to drive growth during the forecast period.
Asia Pacific is expected to witness lucrative growth over the forecast period owing to untapped opportunities in this region along with developing healthcare infrastructure and growing patient awareness levels regarding available treatment options. Increasing incidence rates of chronic diseases coupled with a rise in preference for outpatient settings over hospitals has led clinicians & medical practitioners across this region into recommending clotting factor therapies that can save lives & improve outcomes resulting from surgeries or other treatments required by patients suffering from these conditions (1).
Growth Factors:
- Increasing incidence of bleeding disorders: The global clotting factor market is expected to grow at a CAGR of 5.5% from 2016 to 2021, owing to the increasing incidence of bleeding disorders such as hemophilia and von Willebrand disease.
- Technological advancements in clotting factor therapies: The advent of recombinant clotting factors has revolutionized the treatment landscape for patients with bleeding disorders, and this is expected to drive market growth over the forecast period.
- Rising awareness about available treatments: There is a growing awareness among patients and healthcare professionals about available treatments for bleeding disorders, which is likely to boost demand for clotting factor therapies in the coming years.
- Growing number of approvals for novel therapeutics: The number of approvals granted for novel therapeutics targeting various forms of hemophilia is on the rise, providing a major impetus to market growth over the forecast period.
Scope Of The Report
Report Attributes
Report Details
Report Title
Clotting Factor Market Research Report
By Type
Clotting Factor I, Clotting Factor II, Clotting Factor III, Clotting Factor IV, Others
By Application
Hospitals, Clinics, Ambulatory Surgical Centers
By Companies
Amgen, Novartis, Baxter, Britannia, Capricor, CSL Behring, GlaxoSmithKline, Grifol, Eli Lilly
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
217
Number of Tables & Figures
152
Customization Available
Yes, the report can be customized as per your need.
Global Clotting Factor Market Report Segments:
The global Clotting Factor market is segmented on the basis of:
Types
Clotting Factor I, Clotting Factor II, Clotting Factor III, Clotting Factor IV, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospitals, Clinics, Ambulatory Surgical Centers
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Amgen
- Novartis
- Baxter
- Britannia
- Capricor
- CSL Behring
- GlaxoSmithKline
- Grifol
- Eli Lilly
Highlights of The Clotting Factor Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Clotting Factor I
- Clotting Factor II
- Clotting Factor III
- Clotting Factor IV
- Others
- By Application:
- Hospitals
- Clinics
- Ambulatory Surgical Centers
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Clotting Factor Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Clotting factor is a protein that helps to prevent blood from clotting.
Some of the major companies in the clotting factor market are Amgen, Novartis, Baxter, Britannia, Capricor, CSL Behring, GlaxoSmithKline, Grifol, Eli Lilly.
The clotting factor market is expected to grow at a compound annual growth rate of 5.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Clotting Factor Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Clotting Factor Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Clotting Factor Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Clotting Factor Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Clotting Factor Market Size & Forecast, 2018-2028
4.5.1 Clotting Factor Market Size and Y-o-Y Growth
4.5.2 Clotting Factor Market Absolute $ Opportunity
Chapter 5 Global Clotting Factor Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Clotting Factor Market Size Forecast by Type
5.2.1 Clotting Factor I
5.2.2 Clotting Factor II
5.2.3 Clotting Factor III
5.2.4 Clotting Factor IV
5.2.5 Others
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Clotting Factor Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Clotting Factor Market Size Forecast by Applications
6.2.1 Hospitals
6.2.2 Clinics
6.2.3 Ambulatory Surgical Centers
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Clotting Factor Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Clotting Factor Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Clotting Factor Analysis and Forecast
9.1 Introduction
9.2 North America Clotting Factor Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Clotting Factor Market Size Forecast by Type
9.6.1 Clotting Factor I
9.6.2 Clotting Factor II
9.6.3 Clotting Factor III
9.6.4 Clotting Factor IV
9.6.5 Others
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Clotting Factor Market Size Forecast by Applications
9.10.1 Hospitals
9.10.2 Clinics
9.10.3 Ambulatory Surgical Centers
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Clotting Factor Analysis and Forecast
10.1 Introduction
10.2 Europe Clotting Factor Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Clotting Factor Market Size Forecast by Type
10.6.1 Clotting Factor I
10.6.2 Clotting Factor II
10.6.3 Clotting Factor III
10.6.4 Clotting Factor IV
10.6.5 Others
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Clotting Factor Market Size Forecast by Applications
10.10.1 Hospitals
10.10.2 Clinics
10.10.3 Ambulatory Surgical Centers
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Clotting Factor Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Clotting Factor Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Clotting Factor Market Size Forecast by Type
11.6.1 Clotting Factor I
11.6.2 Clotting Factor II
11.6.3 Clotting Factor III
11.6.4 Clotting Factor IV
11.6.5 Others
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Clotting Factor Market Size Forecast by Applications
11.10.1 Hospitals
11.10.2 Clinics
11.10.3 Ambulatory Surgical Centers
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Clotting Factor Analysis and Forecast
12.1 Introduction
12.2 Latin America Clotting Factor Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Clotting Factor Market Size Forecast by Type
12.6.1 Clotting Factor I
12.6.2 Clotting Factor II
12.6.3 Clotting Factor III
12.6.4 Clotting Factor IV
12.6.5 Others
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Clotting Factor Market Size Forecast by Applications
12.10.1 Hospitals
12.10.2 Clinics
12.10.3 Ambulatory Surgical Centers
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Clotting Factor Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Clotting Factor Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Clotting Factor Market Size Forecast by Type
13.6.1 Clotting Factor I
13.6.2 Clotting Factor II
13.6.3 Clotting Factor III
13.6.4 Clotting Factor IV
13.6.5 Others
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Clotting Factor Market Size Forecast by Applications
13.10.1 Hospitals
13.10.2 Clinics
13.10.3 Ambulatory Surgical Centers
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Clotting Factor Market: Competitive Dashboard
14.2 Global Clotting Factor Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Amgen
14.3.2 Novartis
14.3.3 Baxter
14.3.4 Britannia
14.3.5 Capricor
14.3.6 CSL Behring
14.3.7 GlaxoSmithKline
14.3.8 Grifol
14.3.9 Eli Lilly
